Contents

Series Editors Preface *xv*
Preface *xvi*

Introduction: Successes and Challenges in Antiviral Drug Development *1*
Zhengqiang Wang and Michael J. Sofia
Introduction *1*
Antiviral Drugs Targeting Human Herpesviruses *2*
Antiviral Drugs Targeting Human Immunodeficiency Virus *4*
Drugs Targeting Reverse Transcriptase *4*
Drugs Targeting Protease *6*
Drugs Targeting Integrase Strand Transfer *7*
Drugs Targeting Viral Entry *7*
Drugs Targeting Viral Capsid *8*
Antiviral Drugs Targeting Hepatitis B Virus *9*
Antiviral Drugs Targeting Hepatitis Delta Virus *10*
Antiviral Drugs Targeting Hepatitis C Virus *11*
Antiviral Drugs Targeting Acute RNA Respiratory Viruses *11*
Drugs Targeting Human Influenza Viruses *11*
Drugs Targeting SARS-CoV-2 *14*
New Trends and Challenges in Antiviral Drug Development *15*
References *16*

Part I Human Herpes Viruses *31*

1 Letermovir for the Prevention of CMV Infection in Transplant Recipients *33*
Peter Lischka and Holger Zimmermann
1.1 Background *33*
1.1.1 Cytomegalovirus *33*
1.1.2 Immunocompromised Patients *34*
1.1.3 Patient Groups with a High Risk for CMV Complications *34*
1.1.4 Available CMV Treatments Before Letermovir *35*
1.1.4.1 Antiviral Drugs *35*

1.1.4.2 Dominant Treatment Strategies *37*
1.1.4.3 Unmet Medical Need *38*
1.2 Discovery Phase *38*
1.3 Preclinical Characterization *39*
1.3.1 Antiviral Potency/Selectivity/Inhibitory Profile *39*
1.3.1.1 *In Vitro* Potency Versus Laboratory CMV Strains *39*
1.3.1.2 *In Vitro* Potency Versus Clinical CMV Isolates and Resistance-breaking Profile *40*
1.3.1.3 *In Vivo* Efficacy (Xenotransplant Model) *41*
1.3.1.4 *In Vitro* Antiviral Specificity *42*
1.3.1.5 Other Characteristics of Letermovir's Inhibitory Profile *43*
1.3.1.6 Summary *43*
1.4 Mechanism of Action Studies *43*
1.4.1 Target Identification *43*
1.5 Terminase Inhibitors *46*
1.5.1 Previous and Contemporary Drug Candidates Targeting the Terminase Complex *46*
1.5.2 Letermovir: Same Target, Different Interaction *49*
1.5.3 Advantages of Terminase Inhibitors *49*
1.6 Preclinical Safety Evaluation *50*
1.7 Clinical Development and MAA/NDA Submission *51*
1.7.1 Regulatory Support for Clinical Development *51*
1.7.2 Phase 1 *51*
1.7.2.1 Drug–Drug Interaction Studies *51*
1.7.2.2 Special Populations *51*
1.7.2.3 IV Formulation *52*
1.7.3 Clinical Proof-of-concept *52*
1.7.3.1 Phase 2a Clinical Trial (AIC001-2-001) *52*
1.7.3.2 Emergency IND Treatment of a Lung Transplant Patient with Multiresistant CMV Disease *53*
1.7.3.3 Credentials Established *54*
1.7.4 Letermovir for CMV Prophylaxis in HSCT Patients *55*
1.7.4.1 Phase 2b: First Prophylaxis Trial in HSCT Patients *55*
1.7.4.2 Phase 3 CMV Prophylaxis Trial in HSCT Patients *55*
1.7.4.3 Marketing Approval in HSCT Recipients *57*
1.7.4.4 Further Clinical Development and Real-world Data *57*
1.7.4.4.1 Phase 3 Trial for Extension of the Prophylaxis Period *59*
1.7.4.4.2 Follow-up Trials in Specific Populations *59*
1.7.5 Letermovir for CMV Prophylaxis in KT Patients *60*
1.7.5.1 Phase 3 Noninferiority Trial in KT Recipients *61*
1.7.5.2 Marketing Approval in KT Recipients *61*
1.7.5.3 Further Clinical Development and Real-world Data *62*
1.8 Drug Resistance *62*
1.8.1 Genetic Characterization of Letermovir Resistance *62*
1.9 Letermovir Resistance in Clinical Trials *64*
1.10 Real-world Resistance *65*

1.11 Outlook for Letermovir *65*
Acknowledgments *66*
References *66*

2 Discovery and Development of the Helicase–Primase Inhibitor Pritelivir for the Treatment of Immunocompromised Patients with Resistant HSV Infection *75*
Alexander Birkmann
2.1 HSV Virology and Disease *75*
2.2 Treatment *76*
2.3 Resistant Infections *79*
2.4 Pritelivir Discovery and Target Identification *80*
2.5 Nonclinical Data *82*
2.5.1 *In Vitro* Studies *82*
2.5.2 *In Vivo* Studies *83*
2.5.2.1 Guinea Pig Model for Genital HSV-2 Infection *83*
2.5.2.2 Mouse Model for HSE *84*
2.5.2.3 Pritelivir in Immunocompromised Mouse Model *85*
2.6 Clinical Data *85*
2.6.1 Phase 1 Program *85*
2.6.2 Genital HSV *86*
2.6.3 Resistant Infections *88*
2.7 Pritelivir Resistance *92*
2.8 Conclusion and Outlook *92*
References *93*

Part II Immunodeficiency Virus *101*

3 The Discovery and Early Development of the HIV-1 Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572) *103*
Sherene Min, Soong Hoon Kim, Mark Underwood, Brian Wynne, William Spreen
3.1 Introduction *103*
3.2 Medicinal Chemistry *105*
3.2.1 Discovery of S/GSK1349572 (DTG) *105*
3.2.1.1 Evolution of the Chemical Structure Leading to DTG *105*
3.3 Virology *111*
3.3.1 *In Vitro* Studies Indicated Robust Efficacy and High Barrier to Resistance of DTG *111*
3.4 Clinical Development *115*
3.4.1 PK Studies Supported Once-daily 50 mg Dosing of DTG *115*
3.4.2 Clinical Studies in People Living with HIV-1 *116*
3.4.3 Clinical Studies in Individuals with Prior Treatment Failure *119*
Acknowledgments *120*
References *120*

4 The Discovery and Development of Islatravir (4′-Ethynyl-2-fluoro-2′-deoxyadenosine [EFdA], MK-8591) *127*
Alexa A. Snyder, Xin Wen, Eleftherios Michailidis, Karen A. Kirby, Hiroaki Mitsuya, Stefan G. Sarafianos
4.1 Introduction *127*
4.2 HIV Replication Cycle *128*
4.3 Structure and Function of HIV RT *128*
4.4 DNA Synthesis by RT *130*
4.5 RT Inhibitor Classes *132*
4.6 EFdA Development *133*
4.6.1 4′-Ethynyl Ribose Modifications *134*
4.6.2 2-Fluoro Adenosine Modifications *135*
4.6.3 3′-Hydroxy Ribose Modification *136*
4.7 EFdA: A Compound with 4′-Ethynyl, 2-Fluoro, and 3′-Hydroxy Modifications *137*
4.7.1 Effects of the 4′-Ethynyl Modification on EFdA *137*
4.7.2 Effects of the 2′-Fluoro Modification on EFdA *140*
4.7.3 Effects of the 3′-Hydroxy Modification on EFdA *141*
4.7.3.1 Mechanisms of Inhibition: EFdA *141*
4.7.3.1.1 Biochemical Mechanisms of Inhibition *141*
4.7.3.1.2 Structural Mechanisms of Inhibition *142*
4.8 Mechanism of Resistance/Hypersusceptibility to EFdA *144*
4.8.1 Mechanisms of Viral Resistance to EFdA *144*
4.8.2 Mechanisms of Viral Hypersusceptibility to EFdA *146*
4.8.3 Combination Therapies with EFdA *146*
4.8.4 Synthesis Advances *148*
4.9 Animal Studies *149*
4.9.1 EFdA Pharmacokinetic Studies in Rodents *149*
4.9.2 EFdA Antiviral Activity in Humanized Mice *150*
4.9.3 EFdA Antiviral Activity in Rhesus Macaques *151*
4.9.4 EFdA Long-acting Activity in Various Animals *152*
4.10 Clinical Trials *160*
4.11 Long-acting Methods of Delivery for EFdA Treatment *160*
4.12 NRTTIs as a Drug Class *166*
References *166*

Part III Hepatitis Viruses *185*

5 Discovery of the RNA Interference Therapeutic Imdusiran, a GalNAc-conjugated siRNA *187*
Emily Thi
5.1 Introduction *187*
5.2 Comparison of Preclinical Anti-HBV Efficacy Between Lipid Nanoparticle-encapsulated and GalNAc-conjugated siRNA *188*
5.3 Comparison of Tetravalent Versus Trivalent GalNAc Ligands *190*

5.4 siRNA Selection: Comparison of siRNA Activity Against HBsAg and HBx Targets *191*
5.5 Imdusiran Design and Preclinical Characterization *192*
5.5.1 Abrogation of siRNA Immunostimulatory Potential *192*
5.5.2 Imdusiran siRNA Target Site Sequence *193*
5.6 Imdusiran Antiviral Activity *197*
5.6.1 Imdusiran Antiviral Activity in Primary Mouse and Human Hepatocyte HBV Models *197*
5.6.2 Imdusiran *In Vivo* Antiviral Activity *199*
5.7 Imdusiran Combination Treatment *200*
5.7.1 Imdusiran Combination with Standard of Care and Investigational Agents *200*
5.8 Perspectives *203*
References *206*

6 Discovery and Development of ARO-HBV/JNJ-3989 *211*
Christine I. Wooddell, Oliver Lenz, Thomas Schluep, Man-Fung Yuen, Michael Biermer
6.1 Introduction *211*
6.1.1 Chronic Hepatitis B Virus Infection *211*
6.1.1.1 HBV Structure and Associated Molecular and Cellular Biology *212*
6.1.1.1.1 Clinical Course of HBV Infection *215*
6.2 Development of RNAi Therapeutic ARO-HBV/JNJ-73763989 (JNJ-3989) *216*
6.2.1 RNAi as a Therapeutic Modality *216*
6.2.2 Use of siRNA to Treat HBV Infection *216*
6.2.2.1 JNJ-3989 siRNAs Have Broad Cross-reactivity to HBV Genotypes and HBV Transcripts *217*
6.2.2.1.1 Reduction of Serum HBsAg, HBeAg, and HBV DNA in Mouse Model of Chronic HBV Infection *218*
6.3 Pharmacokinetics and Safety of JNJ-3989 in Humans *218*
6.4 Clinical Studies in Chronically HBV-infected Patients *220*
6.4.1 Direct Antiviral Treatment Approach with JNJ-3989-based Regimens *220*
6.4.1.1 Pharmacological Response to JNJ-3989 with Short-term Treatment *220*
6.4.1.2 REEF-1 Clinical Study *225*
6.4.1.3 REEF-2 Clinical Study *232*
6.4.2 Combination Approaches of JNJ-3989 with Immune Modulation *233*
6.4.2.1 PENGUIN Clinical Study *234*
6.4.2.2 REEF-IT Clinical Study *234*
6.4.3 HBsAg Targeting siRNA JNJ-3989 in Chronic Hepatitis D *236*
6.4.3.1 REEF-D Clinical Study *236*
6.5 Discussion and Perspectives *238*
References *239*

7 The Discovery and Development of Sofosbuvir as the Backbone of HCV Curative Therapies *247*
Michael J. Sofia
7.1 Introduction *247*
7.2 Identification of the 2′-α-F, 2′-β-C-Methyl Cytidine Nucleoside PSI-6130 *248*
7.3 Identification of the 3′,5′-Diisobutyrate Ester Prodrug RG7128 and Clinical Proof-of-concept *250*
7.4 Development of the 5′-Phosphoramidate Uridine Nucleotide Prodrug for Liver Targeting and Clinical Proof-of-concept *251*
7.5 Sofosbuvir: The Backbone of HCV Curative Therapies *255*
7.6 Conclusion *261*
References *261*

8 The Discovery and Development of Harvoni® and Epclusa®: Ending the Interferon Era; Curing All Hepatitis C Genotypes *267*
John O. Link
8.1 Cure *267*
8.2 Introduction *267*
8.3 The Discovery of Ledipasvir [13–15] *270*
8.4 Early Development of Ledipasvir *278*
8.5 Ledipasvir/Sofosbuvir STR Clinical Trial Results and Real-world Effectiveness *280*
8.6 Initiation of a Pangenotypic NS5A Inhibitor Program *283*
8.7 Discovery of the Pangenotypic NS5A Inhibitor Velpatasvir [40–42] *284*
8.8 The Development of Velpatasvir *293*
8.9 Clinical Trial Efficacy and Real-world Effectiveness with the Pangenotypic Sofosbuvir/Velpatasvir STR *297*
8.10 Conclusion *300*
Acknowledgment *300*
Compliance with Ethical Standards *301*
References *301*

Part IV Respiratory Viruses *307*

9 Presatovir: A Once-daily Oral Respiratory Syncytial Virus Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus Infection in Adults and Infants *309*
Richard L. Mackman, Jason Chien, Dustin S. Siegel
9.1 Introduction to Respiratory Syncytial Virus *309*
9.2 Discovery of Presatovir *311*
9.2.1 Lead Identification *311*

9.2.2 Lead Optimization *313*
9.3 Pharmacological Profiling *317*
9.3.1 Mechanism of Action Studies *317*
9.3.2 RSV Animal Models *319*
9.3.3 Spectrum of Activity *320*
9.4 Pharmacokinetics *320*
9.4.1 Preclinical Intravenous and Oral Pharmacokinetics *320*
9.4.2 Lung Distribution Properties *322*
9.4.3 Human Dose Prediction *323*
9.5. Clinical Development *323*
9.5.1 Regulatory Considerations *323*
9.5.2 Phase 1 Program *324*
9.5.3 Phase 2 Program *325*
9.5.4 Treatment Emergent Mutations *327*
9.6 Conclusion *328*
References *328*

10 Remdesivir for the Treatment of COVID-19 and Other Viral Infections with Pandemic Potential *333*
Tomas Cihlar, Meghan S. Vermillion, Joe Llewellyn, Charlotte Hedskog, Richard L. Mackman
10.1 Introduction *333*
10.2 Discovery of Remdesivir *335*
10.2.1 Discovery of 1′-Modified C-Nucleosides *335*
10.2.2 Phosphoramidate Prodrug Optimization for RSV *336*
10.2.3 Synthesis *338*
10.3 Pharmacokinetics *339*
10.3.1 *In Vitro* Metabolism *339*
10.3.2 *In Vivo* Pharmacokinetics *341*
10.3.3 *In Vivo* Lung Metabolism *342*
10.3.4 Oral Delivery and the Discovery of Obeldesivir *343*
10.4 Antiviral Pharmacology *343*
10.4.1 Mechanism of Action *343*
10.4.2 Spectrum of Antiviral Activity *344*
10.4.3 Preclinical Antiviral Efficacy in Animal Models *346*
10.5 Clinical Studies *348*
10.5.1 Phase 1 *348*
10.5.2 Ebola Clinical Development *349*
10.5.3 COVID-19 Clinical Development *349*
10.5.4 Obeldesivir Clinical Development *351*
10.6 Antiviral Resistance *351*
10.7 Summary *353*
Acknowledgments *355*
References *355*

11 Discovery and Clinical Development of Ensitrelvir: An Oral SARS-CoV-2 3CL Protease Inhibitor for the Treatment of COVID-19 *365*
Yuki Tachibana, Ryosuke Shimizu, Haruaki Nobori, Yuko Tsuge, Masaharu Shinkai
11.1 Introduction *365*
11.2 Discovery of Ensitrelvir *369*
11.3 Antiviral Activity of Ensitrelvir *374*
11.3.1 *In Vivo* Antiviral Efficacy of Ensitrelvir *376*
11.3.1.1 Delayed-treatment Model *376*
11.3.1.2 Pharmacokinetics and Pharmacodynamics *378*
11.3.2 Pharmacokinetics *380*
11.3.2.1 Pharmacokinetic Profiles *380*
11.3.2.2 Effect of Food *381*
11.3.2.3 Drug–Drug Interactions *382*
11.3.3 Clinical Trial of Ensitrelvir *383*
11.4 Outlook *384*
11.5 Conclusions *384*
References *385*

12 Discovery and Development of VV116: A Novel Oral Nucleoside Anti-SARS-CoV-2 Drug *389*
Huilong Wang, Yuanchao Xie, Tianwen Hu, Jingshan Shen
12.1 Introduction *389*
12.2 Discovery *390*
12.3 Synthesis *394*
12.4 Preclinical Study *396*
12.4.1 Virology *396*
12.4.2 Mechanism of Antiviral Activity of VV116 *398*
12.4.3 Preclinical Pharmacokinetics *398*
12.4.4 Toxicology *400*
12.5 Clinical Study *400*
12.5.1 Pharmacokinetics *400*
12.5.2 Safety and Tolerability *402*
12.5.3 Phase III Studies *402*
12.6 Future Direction *403*
12.7 Conclusions *404*
References *405*

13 Molnupiravir *411*
Richard K. Plemper
13.1 Introduction *411*
13.2 Mechanism of Antiviral Activity *412*
13.3 Potential for NHC-TP Incorporation into the Host Genome *413*
13.4 Risk of Molnupiravir-enhanced Viral Evolution *415*
13.5 Therapeutic Benefit of Molnupiravir *416*
13.6 Conclusions *418*

Acknowledgments *419*
Conflict of Interest *419*
References *419*

Part V Tropical Disease Viruses *425*

14 Development of a Novel Class of Highly Potent Dengue Virus Inhibitors: From Hit to the Clinical Candidate Mosnodenvir *427*
Suzanne J. F. Kaptein, Bart Kesteleyn, Olivia Goethals, Oliver Ackaert, Dorothée Bardiot, Dominik Kiemel, Guillermo Herrera-Taracena, Ralf Bartenschlager, Marnix Van Loock, Tim H. M. Jonckers, Arnaud Marchand, Patrick Chaltin, Johan Neyts
14.1 Introduction *427*
14.2 Discovery and Optimization of New Dengue Drugs for Prophylaxis *429*
14.2.1 Identification of the Hit CIM020928 *429*
14.2.2 Early SAR Exploration *431*
14.2.3 Early Evaluation of *In Vitro* ADME-Tox and *In Vivo* Pharmacokinetic Properties *433*
14.2.4 Improving Oral Bioavailability *433*
14.2.5 Identification of Preclinical Candidates *434*
14.2.6 Identification of the Clinical Candidate *435*
14.3 Biological Characterization *436*
14.4 Efficacy of Mosnodenvir in Preclinical DENV Infection Models *438*
14.5 Safety Profile and Pharmacokinetics of Mosnodenvir in Humans *440*
14.6 Conclusions *441*
Acknowledgments *441*
References *441*

Part VI Orthopoxvirus *445*

15 Discovery and Development of Brincidofovir *447*
E. Randall Lanier, Scott Foster, Graciela Andrei
15.1 Discovery *447*
15.1.1 Key Points *448*
15.2 Summary of Current and Potential Indications for BCV *449*
15.3 Antiviral Activity *450*
15.3.1 Antiviral Activity Against Double-stranded DNA Viruses *450*
15.3.1.1 Antiviral MOA *451*
15.3.1.1.1 Viruses with Viral DNA Polymerases *451*
15.3.1.1.2 Viruses Without Viral DNA Polymerases *452*
15.3.2 Antiviral Activity Against RNA Viruses *453*
15.3.2.1 Ebola *453*
15.3.2.2 SARS-CoV-2 *454*

15.4 Key Clinical Pharmacology and Safety Considerations *454*
15.4.1 Metabolism and Animal Models *456*
15.5 Clinical Development *457*
15.5.1 Poxviruses *457*
15.5.1.1 Introduction to BCV Animal Models *459*
15.5.1.2 Rabbitpox Model *460*
15.5.1.3 Mousepox Model *461*
15.5.1.4 Scaling to Humans *461*
15.5.1.5 Vaccine Interaction Studies *462*
15.5.1.6 Resistance *462*
15.5.1.7 Other Poxviruses (VACV, Mpox) *462*
15.5.1.7.1 Vaccinia Virus *462*
15.5.1.7.2 Monkeypox Virus *463*
15.5.2 Adenovirus *463*
15.5.2.1 Clinical Experience with Oral BCV for AdV *464*
15.5.2.2 Adenovirus Type and Response to BCV *466*
15.5.2.3 AdV Resistance to BCV *467*
15.5.2.4 ATHENA (IV BCV for AdV) *468*
15.5.3 Cytomegalovirus *469*
15.5.3.1 Clinical Experience with Oral BCV for CMV *469*
15.5.3.2 CMV Resistance to BCV *471*
15.5.4 Polyomaviruses *474*
15.5.4.1 BKV Clinical Data with CDV/BCV *474*
15.5.4.2 JCV Clinical Data with CDV/BCV *475*
15.6 Neurodegenerative Diseases *476*
15.6.1 EBV and Multiple Sclerosis *476*
15.6.2 HSV and Alzheimer's Disease *477*
15.6.3 HHV-6 *478*
15.7 Antiproliferative Activity *478*
15.7.1 Papillomavirus-associated Tumors *479*
15.7.1.1 *In Vitro* Activity Against Papillomavirus-associated Tumors and MOA *479*
15.7.1.2 Animal Studies *480*
15.7.1.3 Clinical Studies *480*
15.7.2 EBV-associated Tumors *481*
15.7.3 Glioblastoma *482*
15.7.4 Antiproliferative MOA *483*
15.8 Summary and Future Directions *483*
Acknowledgments *485*
References *485*

Index *501*